The stock of Acadia Pharmaceuticals Inc (ACAD) has gone down by -1.14% for the week, with a 43.79% rise in the past month and a 20.41% rise in the past quarter. The volatility ratio for the week is 2.32%, and the volatility levels for the past 30 days are 6.08% for ACAD. The simple moving average for the last 20 days is 7.97% for ACAD stock, with a simple moving average of 28.31% for the last 200 days.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a higher price-to-earnings ratio of 15.85x compared to its average ratio, The 36-month beta value for ACAD is at 0.65. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 6 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ACAD is 166.06M, and currently, shorts hold a 9.18% of that float. The average trading volume for ACAD on June 05, 2025 was 2.07M shares.
ACAD) stock’s latest price update
The stock price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has plunged by -0.96 when compared to previous closing price of 21.98, but the company has seen a -1.14% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-05-29 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia P.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Buy.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $35 based on the research report published on May 21, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $22. The rating they have provided for ACAD stocks is “Hold” according to the report published on February 11th, 2025.
Guggenheim gave a rating of “Neutral” to ACAD, setting the target price at $20 in the report published on January 03rd of the current year.
ACAD Trading at 26.57% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.71% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from LAURA BREGE, who proposed sale 14,446 shares at the price of $21.78 back on Jun 04 ’25. After this action, LAURA BREGE now owns shares of Acadia Pharmaceuticals Inc, valued at $314,638 using the latest closing price.
Kihara James, the PRINCIPAL ACCOUNTING OFFICER of Acadia Pharmaceuticals Inc, sale 4,000 shares at $22.50 during a trade that took place back on May 16 ’25, which means that Kihara James is holding 20,395 shares at $90,000 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.23. The total capital return value is set at 0.28. Equity return is now at value 37.24, with 23.03 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.66.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -1.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.49. The receivables turnover for the company is 8.76for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In conclusion, Acadia Pharmaceuticals Inc (ACAD) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
